For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

Rexulti (brexpiprazole) shares positive trial results for treating agitation in Alzheimer's. Following this a bumpy road for another Alzheimer's drug candidate that could supplant the need for antipsychotics to treat behavioral Alzheimer's symptoms, this could be the first such drug approved — if its safety and efficacy data stay on track.

FDA Advisors Endorse Rexulti for Agitation in Alzheimer's Dementia

Drugs Archives - Alzheimer's & Dementia Weekly

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

Rexulti: Side effects, dosage, alternatives, and more

Alzheimer's Disease Insight Report: Current Therapies, Drug

Controversy Surrounds Brexpiprazole's FDA Approval, a New

Otsuka and Lundbeck Announce REXULTI for Alzheimer's Agitation

FDA Approves First Drug to Treat Dementia-Associated Agitation in

FDA OKs First Drug for Agitation in Alzheimer's Dementia

First FDA Approved Medication for Agitation Associated with

SLU Researcher Finds Help for Alzheimer's-Associated Agitation

FDA nod for Rexulti sNDA in treatment of Alzheimer's agitation